AAIC 2025 Abstract
Comparable cumulative exposure and amyloid reduction following donanemab standard and modified titration dosing in participants with early symptomatic Alzheimer’s disease from TRAILBLAZER‐ALZ 6
Trial in peopleInterventions
Abstract
Background: Donanemab is an antibody approved for the treatment of Alzheimer's disease.
